U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT06871527) titled 'Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer' on March 06.
Brief Summary: This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Gastric (Stomach) Cancer
Gastric Adenocarcinoma
Fruquintinib
PD-1 Inhibitor
Tislelizumab
GEJ Adenocarcinoma
Intervention:
DRUG: fruquintinib + tisle...